Key facts
- Notable investors include 3Lines, Presagen, Qubist, SYNthesis BioVentures.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Qubigen
- ·The full record, as it builds
Funding rounds
No funding rounds for Qubigen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Qubigen
Developer of computational drug design technology designed for the development of novel targeted medicines. The company's technology leverages a global federated artificial intelligence system and proprietary workflows to securely analyze protected data, enabling pharmaceutical researchers to generate quality drug candidates efficiently, accelerate structure-activity relationship modeling, and access unique ADMET insights without exposing sensitive intellectual property, ultimately reducing time and resources required for drug discovery.
- Sector
- Healthcare
- HQ
- Parkville, Australia
- Founded
- 2024
- Employees
- 7
- Website
- qubigen.com/
- Ownership
- Privately Held (backing)
Qubigen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Qubigen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Qubigen in its N-PORT filings yet. We sweep new filings monthly.